Being able to reliably identify those patients with the most aggressive cancers early via urine tests, and expediting aggressive therapeutic strategies, may significantly improve outcomes. The scientists believe that the validation of two urinary biomarkers could spell a new way of tailoring treatment…
CLL is the most prevalent leukemia in adults and it is not considered curable without an allogeneic (donor) stem cell transplant. However, advances in therapy have been made, notably the emergence of kinase inhibitors for patients whose disease relapsed, according to the study background…
Fewer women (60 per cent) would be happy to be screened less often if they were found to be at lower risk. More than 940 women from across the UK were asked for their views on the possibility of tailoring breast screening to people’s genetic risk in a study funded by Cancer Research UK and The Eve Appeal…
“The FDA approval has expanded treatments options for many metastatic breast cancer patients, but these new results are showing how effective the drug can also be for breast cancer patients who have already tried endocrine therapies and may be running out of options,” said lead investigator Angela DeMichele, MD, MSCE, associate professor in the division of Hematology/Oncology and Epidemiology and co-leader of the Breast Cancer Research Program at the Abramson Cancer Center. “Combined with the promising results from other trials looking at the effectiveness of this drug, our results indicate that palbociclib can extend the duration of disease control and produce tumor shrinkage in patients with estrogen-receptor positive (ER+) breast cancer, without the debilitating side effects of chemotherapy.” The newly-published phase II trial primarily sought to evaluate disease response and control, while monitoring for the presence of side effects such as neutropenia, an abnormally low white blood cell count. Patients enrolled in the trial had previously undergone several prior chemotherapy and hormonal regimens for metastatic disease…
A similar drug might be able to tame some brain cancers, new research from Columbia University Medical Center has shown. A team led by Antonio Iavarone, MD, professor of neurology and of pathology and cell biology, Institute for Cancer Genetics, previously discovered that a fusion of two proteins (present only in cancer cells and different from the two in CML) drives some cases of glioma, a common form of brain cancer. The team’s most recent study, published in Clinical Cancer Research, looked closely at two patients affected by recurrent glioblastoma with the fused proteins, in a first in-human trial of a drug that targets half of the fusion protein. Those patients, the researchers found, responded particularly well to the drug, with clinical improvement and radiological tumor reduction…
A research collaboration between Griffith and the Malaghan Institute in Wellington, New Zealand has made the discovery that mitochondria are capable of passing through the healthy membrane of a host cell into defective tumour cells, possibly kicking off the rapid proliferation of tumour cells which is the hallmark of cancer. Until now each cell was believed to be a unique entity, with mitochondria and mitochondrial DNA (mtDNA) bound within the cell membrane. …
This work, published in the journal Developmental Cell, opens the door to experiments that are expected to uncover new biology important for a host of conditions, such as neurological diseases, diabetes, obesity, and especially cancer, which has become a hotbed of epigenetic research. “People think cancer is a disease of uncontrolled proliferation, but that’s just one aspect of it,” said Robert Duronio, PhD, professor of biology and genetics and co-senior author. “Cancer is actually a disease of development in which the cells don’t maintain their proper functions; they don’t do what they’re supposed to be doing.” Somehow, the gene regulation responsible for proper cell development goes awry. …
Led by Harold Swartz, MD, PhD, the team published their groundbreaking progress on the decades-old conundrum of how to measure oxygenation in deep-sited tissue in a paper titled, “Deep-Tissue Oxygen Monitoring in the Brain of Rabbits for Stroke Research,” published in Stroke. …
Nicotine from cigarettes is a highly addictive drug that can stimulate cell growth and block cell death – two hallmark characteristics of cancer. Recent evidence also shows that nicotine can cause cancer cells to change their shape, increase their motility and become metastatic. …
Dr. John S. Kuo and colleagues of University of Wisconsin School of Medicine and Public Health, Madison, evaluated two “tumor-selective” fluorescent agents — called CLR1501 and CLR1502 — for their ability to differentiate brain tumors from normal brain tissue in mice…